LivaNova PLC (LIVN) ニュース

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year...

Form 3 - Initial statement of beneficial ownership of securities

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief...

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Results published in two articles in Brain Stimulation LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society...

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will...

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Top-line results compared to baseline at six months: Median apnea-hypopnea index reduction of 66.2% Median oxygen desaturation index reduction of...

Form 8-K - Current report